Evidence map›Paper›PMID 39916528›Full record

Observational studyJournal of rehabilitation medicine2025

Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real-world practice.

Richard D Zorowitz, Jorge Jacinto, Stephen Ashford, Mathieu Beneteau, Pascal Maisonobe, Christian Hannes, Alberto Esquenazi

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of rehabilitation medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Observational
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Richard D ZorowitzMedStar Health, Washington and Georgetown University School of Medicine, Washington, DC, USA. Richard.Zorowitz@medstar.net.
Jorge JacintoCentro de Medicina de Reabilitação de Alcoitão, Serviço de Reabilitação de Adultos 3, Estoril, Portugal.
Stephen AshfordLondon North West University Healthcare NHS Trust, Regional Hyper-Acute Rehabilitation Unit, Northwick Park Hospital, London, UK.
Mathieu BeneteauIpsen, Boulogne-Billancourt, France.
Pascal MaisonobeIpsen, Boulogne-Billancourt, France.
Christian HannesIpsen, Munich, Germany.
Alberto EsquenaziMossRehab Jefferson Health, Elkins Park, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDescribe abobotulinumtoxinA (aboBoNT-A) dosing parameters in the real-world management of lower limb spasticity (LLS).

methodsProspective, observational study (NCT0​4050527) following ambulatory adults with unilateral LLS treated with aboBoNT-A.

resultsThe effectiveness population included 384 adults with LLS. Across the study, total lower limb doses were higher in patients who received only lower limb injections (n = 131, median 771U) than those who also received ≥ 1 upper limb injection (n = 253, 567U). Total doses increased over subsequent cycles in both subgroups. Six muscles (gastrocnemius medial and lateral heads, soleus muscle, tibialis posterior, flexor digitorum longus, and flexor hallucis longus) were identified as the main targets for the treatment of LLS; other lower limb muscles were injected in fewer than 15% of patients. The most frequent therapy interventions (mean ± SD of 1.8 ± 1.3h/week with a qualified therapist and 5.3 ± 5.9h/week self-rehabilitation in Cycle 1) were task-specific practice, passive stretch, strength training, and positioning.

conclusionsThis study demonstrates how a diversity of muscle patterns are currently treated in routine practice where the primary goal was related to the lower limb and highlights important issues for further debate, such as potential underdosing and the need to balance upper and lower limb priorities when devising a treatment plan.

Indexed as

Botulinum Toxins, Type ALower ExtremityMuscle, SkeletalMuscle SpasticityNeuromuscular AgentsAdultAgedFemaleHumansInjections, IntramuscularLongitudinal StudiesMaleMiddle AgedProspective StudiesTreatment OutcomeabobotulinumtoxinABotulinum Toxins, Type ANeuromuscular Agents

Identifiers

PMID39916528
PMCPMC11836465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.